One Patient. That's All It Took to Kill This Alzheimer's Trial.
Ionis pulled the plug on an Alzheimer's trial for people with Down syndrome after enrolling just one patient in 14 months. The drug wasn't the problem; the brutal reality of rare disease recruitment was.
Imagine opening a restaurant, spending months on the build-out, hiring the staff, printing the menus, and then closing after serving exactly one customer.
That's essentially what just happened to Ionis Pharmaceuticals. The biotech giant launched a clinical trial in late 2024 to test an experimental Alzheimer's treatment in people with Down syndrome. Fourteen months later, they pulled the plug. Total patients enrolled: one.
The drug, called ION269, was an antisense oligonucleotide: a type of therapy that works by intercepting the genetic instructions cells use to build proteins. In this case, ION269 was designed to reduce production of amyloid precursor protein, or APP. Think of APP as the raw material your brain uses to make amyloid plaques, the sticky clumps that are a hallmark of Alzheimer's disease.
For people with Down syndrome, this is an especially cruel problem.
The Population Nobody's Treating
People with Down syndrome carry an extra copy of chromosome 21, and that chromosome happens to house the gene for APP. Their brains produce more of the protein than typical, which means they start building amyloid plaques early. By their 40s and 50s, over 50% will develop Alzheimer's disease. Some estimates put the number closer to 90%.
You'd think these patients would be first in line for the new wave of anti-amyloid drugs, the ones that have been grabbing headlines and FDA approvals — drugs like Eli Lilly's donanemab (brand name Kisunla) and Eisai/Biogen's lecanemab (Leqembi). But there's a catch.
These drugs come with a known side effect called ARIA (amyloid-related imaging abnormalities). In plain English: brain swelling and bleeding. It's a manageable risk for most people, but for people with Down syndrome, who already have elevated vulnerability to brain bleeds, the math gets scary fast. That's why the major anti-amyloid trials have effectively shut them out.
So Ionis had a clever idea. Instead of clearing amyloid after it builds up (and risking bleeding), why not stop the brain from making so much of it in the first place? ION269 would go upstream, cutting off the supply rather than mopping up the mess. It was an elegant approach to a brutal problem.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
It just couldn't find patients.
Why Filling One Trial Seat Was This Hard
An Ionis spokesperson said the decision to terminate came down to "multiple factors, including slow enrollment," and stressed it had nothing to do with safety concerns about the drug itself. But that's almost what makes this story sadder; the molecule never even got a fair shot.
Recruiting for clinical trials in the Down syndrome community is one of the hardest jobs in medicine. The reasons stack up like a pile of regulatory paperwork.
First, the eligible population is small. Down syndrome itself isn't common, and the trial needed adults at a specific stage of cognitive health. That already narrows the pool dramatically.
Then there's the consent issue. People with intellectual disabilities require carefully adapted consent processes, often involving family members and caregivers. Trials need simplified materials and extra support; things that take time, money, and specialized expertise to build.
Caregiver burden is real, too. Clinical trials demand frequent visits, brain scans, blood draws, and memory tests. For a caregiver already managing the daily needs of an adult with Down syndrome, signing up for months of hospital trips is a big ask. Many families simply can't swing it.
And here's the part that doesn't get discussed enough: trust. The Down syndrome community has watched the pharmaceutical industry develop Alzheimer's drugs for decades without including them. When a trial finally does show up, some families are understandably skeptical about whether the system actually has their best interests at heart.
Lilly Steps Up to the Plate
Ionis may have walked away, but the story doesn't end here. Eli Lilly is planning a study called ALADDIN: a Phase 4 trial that will test donanemab in approximately 60 non-demented adults with Down syndrome, ages 35 to 50.
The trial is expected to start around August 2026. It's a double-blind, placebo-controlled study running for about 12 months, followed by a 12-month extension. The primary question is simple but important: can donanemab safely reduce brain amyloid levels in this population without causing the bleeding problems everyone is worried about?
Participants will get IV infusions every four weeks, with the dose ramping up to a target of 1,400 mg. Lilly is going in with eyes wide open; the trial protocol includes pre-treatment MRI scans and genetic testing to monitor ARIA risk.
This is a significant move. It directly addresses the safety gap that's kept Down syndrome patients locked out of every approved Alzheimer's treatment. But it also sets up a fascinating tension. Donanemab works by clearing amyloid plaques, exactly the mechanism that carries bleeding risk. Ionis was trying the potentially safer "turn off the faucet" approach and couldn't get patients through the door. Lilly is going with the "drain the bathtub" strategy that everybody's worried about and betting they can manage the risks.
The Bigger Picture: Rare Diseases and the Enrollment Problem
Ionis isn't some fly-by-night startup that ran out of money. The company has three FDA-approved neurological drugs already on the market, over ten mid-to-late-stage programs, and just outlined plans for five Phase 3 readouts and four NDA submissions in 2026. They have deep pockets and deep expertise. If they can't recruit for a Down syndrome Alzheimer's trial, that tells you something about the structural barriers involved.
The good news is that infrastructure is slowly being built. An initiative called the Trial Ready Cohort for Down Syndrome (TRC-DS) has pre-screened over 350 adults with Down syndrome to create a pool of trial-ready participants. The Alzheimer's Clinical Trials Consortium for Down Syndrome (ACTC-DS), led by researcher Michael Rafii, has been working with advocacy organizations like the National Down Syndrome Society and the Global Down Syndrome Foundation to improve outreach and trust.
These efforts take years to pay off. Ionis apparently couldn't wait that long.
The company says it's now prioritizing "high potential programs," including a Phase 3 trial for Angelman syndrome, another rare genetic condition. ION269 has been dropped from the pipeline entirely. No second chances, no redesign, no expanded sites.
What This Means for the Down Syndrome Community
Advocacy leader Hampus Hillerstrom of LuMind IDSC has pointed out that approved anti-amyloid drugs currently exclude Down syndrome patients because their safety simply hasn't been tested in this group. It's a Catch-22 worthy of Joseph Heller: you can't get the drug because there's no safety data, and there's no safety data because you can't get into the trials.
Lilly's ALADDIN study could begin to break that cycle, but it's still over a year away from enrolling its first patient. And if Ionis's experience is any guide, filling those 60 slots won't be a walk in the park either.
For the roughly 200,000 adults living with Down syndrome in the United States, the clock is ticking. Amyloid doesn't wait for trial logistics to sort themselves out. Every year that passes without answers is another year where families face a disease they can see coming but can't do anything about.
One patient enrolled. One drug abandoned. The population that needs Alzheimer's treatments most is still waiting in line.
Clinical and Regulatory
4 min read
Roche's New Breast Cancer Pill Has a Secret Weapon
Roche's oral breast cancer drug giredestrant just got its FDA date, and its secret weapon isn't the drug itself. It's the combination strategy that cut disease progression by 62% in the patients who need it most.
